FOx Biosystems, a spin-off company from the KU Leuven, uses an innovative biosensor technology that allows both kinetic characterization and quantifications directly in the sample within the life sciences sector. Users are able to generate high quality biomolecular data in a fast, straightforward and cost-effective way ideally suited for industry 4.0. The aim is therefore to revolutionize the life science industry and research market with this modern technique.
FOx Biosystems applied for financial support with VLAIO and Interreg (Trans Tech Diagnostics (TTD) and CrossRoads) by submitting development projects. VLAIO (“Vlaams Agentschap Innoveren & Ondernemen”) is a department of the Flemish Government which encourages and supports innovation and entrepreneurship. CrossRoads and TTD form part of the European program Interreg and stimulate cross-border cooperation between Flanders and the Netherlands. These projects mainly focus on companies with interesting, innovative, and technically feasible ideas. Regarding the latter, FOx Biosystems cooperates with the Dutch company Unitron NV and the Belgian company L.E.T. on the one hand, and Prof. J. Lammertyn from KU Leuven, head of the research group Biosensing and Prof. L. Michiels from the UHasselt, head of the research group Immunology – Biochemistry on the other hand.
Thanks to the high quality of the submitted proposals, a total amount of €884 000 was awarded to FOx Biosystems. This additional budget will be used to upscale and optimize the fiber optic probe manufacturing process, and hire extra employees for bioassay development and performance. Check out our job openings on www.flanders.bio/en/jobs/ and www.foxbiosystems.com/careers.html.
About FOx Biosystems
FOx Biosystems was founded in 2017 as a spin-off from the KU Leuven. Last year they secured €4 million in capital with LRM (Limburgse Investeringsmaatschappij), the Gemma Frisius Fund and several biotech investors. The company headquarters is located in Bioville, the bio-incubator in Diepenbeek (Belgium), where both office and laboratory spaces are established.
The biosensor technology of FOx Biosystems has many advantages compared to existing biomolecular analysis instruments. The ease of use, speed, cost-effectiveness and the minimal time for sample pre-processing, even in complex media, are key assets of the device. This innovative sensor technology, based on optical fibers, enables the users to generate high quality biomolecular data such as affinity data, kinetic data and concentration measurements from sub pM up to high µM. The innovative platform increases the efficiency of pharmaceutical drug research and development and allows flexible bioprocess monitoring.
FOx Biosystems sells instruments, reagents and services. Currently, three custom-made probes are available for purchase.
More information can be found on the website: www.foxbiosystems.com.